# Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

> **NCT00620113** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 287 (actual)

## Conditions studied

- Osteoporosis Postmenopausal

## Interventions

- **DRUG:** Odanacatib
- **DIETARY_SUPPLEMENT:** Vitamin D3
- **DIETARY_SUPPLEMENT:** Calcium carbonate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00620113
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-03
- **Primary completion:** 2009-05-29
- **Final completion:** 2009-05-29
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620113, "Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00620113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*